Future trend of biopharmaceutical cro in 2015

1、 In 2015, the cro market scale reached $70 billion in biomedical outsourcing, which means that pharmaceutical companies engage in their own core business and transfer the non core business originally completed by the enterprise to more efficient external suppliers in the form of contracts, so as to save time and money for the company and achieve the strategic choice purpose of enhancing competitiveness The R & D time of major new drugs is usually more than 10 years R & D outsourcing can shorten the R & D time by 30% Take the case of major anti-cancer drugs with annual sales of more than 2 billion US dollars In the morning, even one month in the city, the potential revenue of 200 million US dollars can be increased, which does not include the labor cost and equipment cost of pharmaceutical enterprises Therefore, as pharmaceutical companies increasingly rely on cro as their R & D external resources, cro is also facing great development potential According to the analysis report on the market prospect and investment strategic planning of China's biomedical outsourcing industry in 2015-2020 released by the prospective industry research institute, in 2006, the global cro market scale was US $19.6 billion, reaching US $55.2 billion in 2013, with an average compound growth rate of 16.42% With a growth rate of 15%, it is estimated that the global cro market will reach US $70 billion in 2015, of which pre clinical research accounts for 59% and pre clinical trials 41% II Analysis of global cro development trend in 2015 ● continuous expansion of service scope At present, the outsourcing service business of biomedical R & D has developed from the initial limited services of drug discovery, preclinical research, pharmacogenomics, drug safety evaluation, etc to dozens of contents, even including data management and analysis, informatics, policy and regulation consultation, product registration, production and packaging, promotion, market, product release and sales support, as well as various related businesses There are many fields, such as industry consultation, and new service content increases every year The scope of R & D outsourcing service in biomedical field has been greatly expanded In recent years, multinational companies in developed countries have accelerated the transfer of biomedical research to developing countries, such as India, China, Brazil, etc In 1996, MDS Pharma service, an international R & D outsourcing service company in the United States, invested and established the first real contract research company in China to engage in clinical trials of new drugs Later, the United States, Kuntai, cowens and so on successively set up branches in China.